ArticleFrontiers in immunology2026
Efficacy and safety of TACE combined with MWA followed by immune checkpoint inhibitors and anti-VEGF/tyrosine kinase inhibitors in hepatocellular carcinoma beyond the up-to-7.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have shown that locoregional therapy combined with systemic treatment provides survival benefits with manageable safety in patients with intermediate-to-advanced large hepatocellular carcinoma (HCC). However, the optimal treatment strategy for HCC beyond the up-to-7 criteria remains unclear because of the high tumor burden and recurrence risk. This study aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) plus microwave ablation (MWA) followed by targeted immunotherapy in patients with HCC beyond the up-to-7 criteria. Methods: This single-center retrospective study included patients with HCC beyond the up-to-7 criteria treated at our institution between October 2018 and December 2023. The study group received TACE plus MWA followed by ICIs combined with anti-VEGF/TKI therapy, while the control group received TACE followed by ICIs combined with anti-VEGF/TKI therapy. The primary endpoint was progression-free survival (PFS) assessed by mRECIST, and the secondary endpoints were overall survival (OS) and treatment-related adverse events (TRAEs).Baseline data were balanced using a one-to-one propensity score matching (PSM) and inverse probability of treatment weighting (IPTW). Result: Among the 80 included patients, the median follow-up time was 68.4 months. Thirty patients had hepatitis B and 40 had hepatitis C. Patients were classified as BCLC stage A-C, with a median tumor size of 7.1 cm. The control and study groups included 41 and 39 patients, respectively. The median PFS was 5.7 months(95%CI:3.617-7.716) versus 11.4 months(95%CI:8.741-14.125), and the median OS was 16.5 months(95%CI:10.863-22.071) versus 40.2 months (95%CI:34.302-46.165), respectively (both Conclusion: TACE combined with MWA followed by immune checkpoint inhibitors and anti-VEGF/TKI therapy prolonged progression-free and overall survival in patients with HCC beyond the up-to-7 criteria, with manageable safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.